ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0233

Abatacetp in Spanish Patients with Arthritis Rheumatoid and Interstitial Lung Disease. Multicenter Study of 263 Patients

C. Fernandez-Diaz1, Santos Castañeda2, Rafael Melero3, Francisco Miguel Ortiz Sanjuan4, Antonio Juan-Mas5, Carmen Carrasco Cubero6, Raquel Almodovar7, Sebastian Rodriguez-Garcia8, C. Aguilera-Cros9, Ignacio Villa10, S. Ordoñez11, Enrique Raya12, C. Ojeda13, Manuel Jose Moreno-Ramos14, Gema Bonilla15, Susana Romero-Yuste16, Ana Ruibal-Escribano17, Jose Luis Andreu Sanchez18, R. Exposito19, Javier Loricera20, Natalia Mena-Vazquez21, Ana Urriticoechea22, C. Peralta23, Luis Arboleya24, Francisco Javier Narváez25, O. Maiz26, Julia Fernandez Melon27, P Vela28, Ivan Castellvi29, I. Cabezas30, Alejandra Lopez Robles31, Patricia Carreira Delgado32, Juan M. Blanco-Madrigal33, N. Del-val-del-amo34, E Salgado35, B. Garcia-magallon36, Cristina Hidalgo Calleja37, Mireia Corbeto Lopez38, A. Perez39, S. Castro40, Juan Ramón De dios41, Andrea García Valle42, R Lopez43, Angel García Aparicio44, EC Cervantes45, C Gonzalez46, N Alvarez-Rivas47, L. Perez48, Miguel Ángel González-Gay49 and Ricardo Blanco50, 1H. Marqués de Valdecilla, Madrid, Spain, 2Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, 3CHU. VIgo, Vigo, Spain, 4Rheumatology Department, HUP La Fe, Valencia, Spain, 5Son Llàzer University Hospital, Mallorca, Spain, 6H. Mérida, Mérida, Spain, 7Fundación Alcorcón University Hospital, Madrid, 8La Princesa University Hospital, Madrid, Spain, 9H.Virgen del Rocio, Sevilla, Spain, 10H. Torrelavega, Santander, Spain, 11H. Arnau Vilanova, LLeida, Spain, 12San Cecilio Clinic Universitary Hospital, Granada, Spain, 13H. Virgen de la Macarena, Sevilla, Spain, 14Arrixaca University Hospital, Murcia, 15Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Spain, 16H Pontevedra, Coruna, Spain, 17Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, 18Hospital Universitario Puerta de Hierro, Majadahonda, Spain, 19H. Laredo, Laredo, Spain, 20Hospital Universitario Marqués de Valdecilla, Santander, Spain, 21Hospital Regional Universitario de Málaga, Málaga, Spain, 22Can Misses, Ibiza, Spain, 23H. Clinico Zaragoza, Zaragoza, Spain, 24H. Oviedo, Oviedo, Spain, 25Hospital Bellvitge, BARCELONA, Spain, 26H. Donosti, Donosti, Spain, 27H. Son Espases, Mallorca, Spain, 28H Alicante, Alicante, Spain, 29Hospital Santa Creu i Sant Pau, Barcelona, Spain, 30H. Río Ortega, Valladolid, Spain, 31H. León, León, 32H. 12 de octubre, Madrid, Spain, 33Basurto University Hospital, Bilbao, Spain, 34Complejo Hospitalario de Navarra, Pamplona, Spain, 35CHU Ourense, Ourense, Spain, 36H. Huesca, Zaragoza, Spain, 37Hospital Universitario Salamanca, Salamanca, Spain, 38Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain, 39H. Puerta del Mar, Cadiz, Spain, 40H. Joan XXIII, Tarragona, Spain, 41H. Alava, Alava, Spain, 42H. Palencia, Palencia, Spain, 43H. Negrin, Las Palmas, Spain, 44H. Mostoles, Madrid, Spain, 45H. Santiago de compostela, Santiago, Spain, 46H. Valladolid, Valladolid, Spain, 47H. S Agustin, Aviles, Spain, 48Hospital Universitario Virgen de las Nieves, Granada, Spain, 49Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 50Hospital Universitario Marques de Valdecilla, Santander, Spain

Meeting: ACR Convergence 2020

Keywords: Biologicals, interstitial lung disease, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: RA – Treatments Poster I: RA Treatments & Their Safety

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: To assess the efficacy of abatacept (ABA) in Rheumatoid Arthritis (RA) patients with Interstitial Lung Disease (ILD) (RA-ILD).

Methods: Observational multicenter study of RA-ILD patients treated with at least 1 dose of ABA. ILD was diagnosed by high-resolution computed tomography (HRCT). We analyzed the following variables at baseline (ABA initiation), 12 months, and at the end of the follow-up: a) Modified Medical Research Council (MMRC) scale (1-point change), b) Forced Vital Capacity (FVC) or Diffusion Lung Capacity for Carbon Monoxide (DLCO) (improvement or worsening ≥10%), c) HRCT, d) DAS28ESR, and e) corticosteroid sparing effect

Results: We studied 263 RA-ILD patients (150 women/113 men; mean age 64.6±10 years). At baseline, they had a median duration of ILD of 1 [0.25-3.44] years, moderate or severe degree of dyspnea (MMRC grade 2, 3 or 4) (40.3%), FVC (% of the predicted) mean±SD 85.9±21.8%, DLCO (% of the predicted) 65.7±18.3, and DAS28ESR: 4.5±1.5. The ILD patterns were: Usual Interstitial Pneumonia (UIP) (40.3%), Non-Specific Interstitial Pneumonia (NSIP) (31.9%), and others (27.8%). ABA was prescribed at standard dose, intravenously (25.5%) or subcutaneously (74.5%). After a median follow-up of 12 [6-36] months the following variables did not show worsening: dyspnea (MMRC) (91.9%); FVC (87.7%); DLCO (90.6%); chest HRCT (76.6%). A significant improvement of DAS28ESR from 4.5±1.5 to 3.1±1.3 at the end of follow-up (p< 0.001) and a corticosteroid sparing effect from a median 7.5 [5-10] mg/day to 5 [2.5-7.5] mg/day at the end of follow-up; p < 0.001 was also observed. ABA was withdrawn in 62 (23.6%) patients due to adverse events (n=30), articular inefficacy (n=27), ILD worsening (n=3), and other causes (n=2).

Conclusion: ABA may be an effective and safe treatment for patients with RA-ILD.


Disclosure: C. Fernandez-Diaz, None; S. Castañeda, Roche, 2; R. Melero, None; F. Ortiz Sanjuan, None; A. Juan-Mas, None; C. Carrasco Cubero, None; R. Almodovar, None; S. Rodriguez-Garcia, None; C. Aguilera-Cros, None; I. Villa, None; S. Ordoñez, None; E. Raya, None; C. Ojeda, None; M. Moreno-Ramos, None; G. Bonilla, None; S. Romero-Yuste, None; A. Ruibal-Escribano, None; J. Andreu Sanchez, None; R. Exposito, None; J. Loricera, None; N. Mena-Vazquez, None; A. Urriticoechea, None; C. Peralta, None; L. Arboleya, None; F. Narváez, None; O. Maiz, None; J. Fernandez Melon, None; P. Vela, None; I. Castellvi, None; I. Cabezas, None; A. Lopez Robles, None; P. Carreira Delgado, None; J. Blanco-Madrigal, None; N. Del-val-del-amo, None; E. Salgado, None; B. Garcia-magallon, None; C. Hidalgo Calleja, None; M. Corbeto Lopez, None; A. Perez, None; S. Castro, None; J. De dios, None; A. García Valle, None; R. Lopez, None; A. García Aparicio, None; E. Cervantes, None; C. Gonzalez, None; N. Alvarez-Rivas, None; L. Perez, None; M. González-Gay, None; R. Blanco, None.

To cite this abstract in AMA style:

Fernandez-Diaz C, Castañeda S, Melero R, Ortiz Sanjuan F, Juan-Mas A, Carrasco Cubero C, Almodovar R, Rodriguez-Garcia S, Aguilera-Cros C, Villa I, Ordoñez S, Raya E, Ojeda C, Moreno-Ramos M, Bonilla G, Romero-Yuste S, Ruibal-Escribano A, Andreu Sanchez J, Exposito R, Loricera J, Mena-Vazquez N, Urriticoechea A, Peralta C, Arboleya L, Narváez F, Maiz O, Fernandez Melon J, Vela P, Castellvi I, Cabezas I, Lopez Robles A, Carreira Delgado P, Blanco-Madrigal J, Del-val-del-amo N, Salgado E, Garcia-magallon B, Hidalgo Calleja C, Corbeto Lopez M, Perez A, Castro S, De dios J, García Valle A, Lopez R, García Aparicio A, Cervantes E, Gonzalez C, Alvarez-Rivas N, Perez L, González-Gay M, Blanco R. Abatacetp in Spanish Patients with Arthritis Rheumatoid and Interstitial Lung Disease. Multicenter Study of 263 Patients [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/abatacetp-in-spanish-patients-with-arthritis-rheumatoid-and-interstitial-lung-disease-multicenter-study-of-263-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/abatacetp-in-spanish-patients-with-arthritis-rheumatoid-and-interstitial-lung-disease-multicenter-study-of-263-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology